BIPH - BIOPHAN TECHGS (OTCBB) Date Open High Low Last Change Volume % Change 01/09/04 0.78 1.08 0.74 1.01 +0.31 10077000 +44.29%
Composite Indicator Trend Spotter (TM) Buy
Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Buy 20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy 20-Day Average Volume - 2063740
Medium Term Indicators 40 Day Commodity Channel Index Buy 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Buy 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy 50-Day Average Volume - 1590894
Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy 100-Day Average Volume - 1022703
posted
A lot of traders are emailing me to find out pre-market what my plays are for the day. Very often I have to answer them that I don't know until the bell goes off. If it comes out of the gate hot in the morning, I get in for the day. Occasionally though, one is in my sights ahead of time. I had fun with this on Friday (made a few bucks) and I think it is good for another run on Monday. I'll watch for a dip but I am going to be getting back in. They have a very good website listed above and here is a good piece.
Biophan is developing technology to make biomedical devices safe, both implanted devices and those used in surgical and diagnostic procedures, and to reduce interference that these devices cause to Magnetic Resonance Imaging (MRI) image quality.
Today, many devices (such as pacemakers and surgical devices) are not used with MRI due to safety concerns involved with the MRI environment, including heating of devices and metal wire leads, which can cause tissue damage. Most MRI imaging centers today refuse to allow pacemaker patients, and those with other implanted medical devices, to undergo MRI imaging due to safety problems.
In order to make the most effective use of MRI, in addition to resolving the safety concerns, it is desirable that the device not interfere with the MRI image quality. Our solutions also address this objective.
MRI is one of the most important diagnostic tools in medicine. Biophan currently has 42 patents pending on this technology and exclusive licenses for three issued U.S. patents.
Our solutions include coatings, filters, and photonics. Information regarding each of our solutions is provided on this website. For additional technical information, please contact us at info@biophan.com or 585-214-2441.
Shareholder Information Exchange OTC Bulletin Board
Stock Information (BIPH) 1.01 (+0.31 Change) Minimum 20 minutes delayed
Listed Security BIPH Common Stock
Transfer Agent Continental Stock Transfer & Trust Company 2 Broadway, 19th Floor New York, NY 10004 Corporate Counsel Nixon Peabody, LLP Clinton Square P.O. Box 3051 Rochester, NY 14603 Independent Accountants Goldstein Golub Kessler LLP 1185 Avenue of the Americas, Suite 500 New York, NY 10036-2602
Biophan's Nanotechnology Portfolio Expands; US Patent Granted Which Provides Biophan Additional Nanotechnology Rights
***
Health/Medical Writers / Business Editors ROCHESTER, N.Y.--(BUSINESS WIRE)--BIPH-- Biophan Technologies, Inc. (OTC BB: BIPH), an innovator, developer, and marketer of advanced biomedical technology, today announced that its licensor for nanomagnetic particle technologies has been issued a U.S. patent, which covers the use of nanomagnetic particle technology on medical devices including catheters, guidewires, and endoscopes, and other medical devices. The patent was issued to Nanoset, LLC, which has provided Biophan with the worldwide exclusive medical rights to the technology. The nanotechnology patents are a subset of over 50 pending patents filed by Nanoset and Biophan and are a core driver of Biophan's strategic plan of creating and maintaining a dominant position in this important new growth area. Biophan and Nanoset have had additional patents allowed by the U.S. patent office and will announce these as they are issued. The patent can be viewed at www.biophan.com/patents/3.html. "Working with Nanoset, we have filed nine additional patent applications in this important area of nanotechnology, all focused on approving MRI imaging and safety for biomedical devices," noted Michael Weiner, Biophan's chief executive officer. "The newly issued patent includes 43 claims for sheaths and encapsulations which provide improved MRI safety and imaging quality, with minimal impact on existing manufacturing processes." Mr. Weiner concluded, "This is the second U.S. patent issued to Nanoset, and expands the application of novel nanomagnetic shielding technology to surgical tools that today cannot effectively be used in a Magnetic Resonance Imaging (MRI) environment." About Nanoset, LLC Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings. Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings. Nanoset and Biophan are jointly developing technologies for the medical device industry. About Biophan Technologies, Inc. Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. KEYWORD: NEW YORK INDUSTRY KEYWORD: BANKING MEDICAL MEDICAL MEDICAL DEVICES MEDICAL MEDICAL PHARMACEUTICAL BIOTECHNOLOGY PRODUCT SOURCE: Biophan Technologies, Inc. CONTACT INFORMATION: Trilogy Capital Partners, Inc. Investor Relations: Racquel Rivera, 800-330-6540 racquel@trilogy-capital.com or Press Interviews: Biophan Technologies, Inc. Michael Weiner, 585-214-2441
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
